Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Nov 15;16(1):220.
doi: 10.1186/s12883-016-0741-x.

Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis

Daan Fritz  1 , Diederik van de Beek  1 , Matthijs C Brouwer  2
Affiliations
Meta-Analysis

Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis

Daan Fritz et al. BMC Neurol. .

Abstract

Background: Neurosarcoidosis is a rare variant of sarcoidosis and is only described in small cohort studies. We define clinical features, treatment and outcome of patients with neurosarcoidosis over the last 35 years.

Methods: We performed a systematic review and meta-analysis of studies on neurosarcoidosis published between 1980 and 2016. Studies were included if they reported at least 5 cases. Studies describing one specific neurological presentation were excluded.

Results: We identified 29 articles describing 1088 patients diagnosed between 1965 and 2015. Neurosarcoidosis occurred in 5% of patients with systemic sarcoidosis. Mean age at presentation was 43 years and neurological symptoms were the first clinical manifestation of sarcoidosis in 52%. The most commonly reported feature of neurosarcoidosis was cranial neuropathy in 55%, with the facial and optic nerve most commonly affected, followed by headache in 32%. Pleiocytosis and elevated CSF protein were found in 58 and 63%. MRI of the brain showed abnormalities in 70%. Chest X-ray, chest CT, or gallium-67-scintigraphy showed findings consistent with sarcoidosis in 60%, 70% and 69%, respectively. First line therapy with corticosteroids was initiated in 434 of 539 patients (81%). Second and third line therapy was started in 27 and 9%. Outcome consisted of complete remission in 27%, incomplete remission in 32%, stable disease in 24%, deterioration in 6% and death in 5%.

Conclusion: Neurosarcoidosis has a heterogeneous clinical presentation and the diagnosis can be difficult because of low sensitivity of ancillary investigations. New treatments have emerged, but nevertheless one third of patients do not respond to treatment. Prospective cohort studies and RCTs on treatment are urgently needed.

Keywords: Auto-immune disease; Clinical neurology; Meta-analysis; Neurosarcoidosis; Systematic review; Systemic disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow chart of inclusion of studies
Fig. 2
Fig. 2
Proportion of treatment used according to timeframe
Fig. 3
Fig. 3
Temporal trend of patients with neurosarcoidosis with reported substantial improvement
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153–2165. doi: 10.1056/NEJMra071714. - DOI - PubMed
    1. Thomas KW, Hunninghake GW. Sarcoidosis. JAMA. 2003;289(24):3300–3303. doi: 10.1001/jama.289.24.3300. - DOI - PubMed
    1. Nozaki K, Judson MA. Neurosarcoidosis. Curr Treat Options Neurol. 2013;15(4):492–504. doi: 10.1007/s11940-013-0242-9. - DOI - PubMed
    1. Segal BM. Neurosarcoidosis: diagnostic approaches and therapeutic strategies. Curr Opin Neurol. 2013;26(3):307–313. doi: 10.1097/WCO.0b013e3283608459. - DOI - PubMed
    1. Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. Lancet Neurol. 2004;3(7):397–407. doi: 10.1016/S1474-4422(04)00805-1. - DOI - PubMed

Supplementary concepts